|
DOSAGE
|
Post-Op Inflammation: 1 gtt TID 1 day prior to surgery, continue TID day of, then for 2 weeks. Shake prior to use
|
|
GENERIC
|
nepafenac suspension 0.1%
|
|
INDICATIONS
|
NEVANAC® 0.1% is indicated for the treatment of pain and inflammation associated with cataract surgery.
|
|
MECHANISM OF ACTION
|
Prodrug of amfenac a COX inhibitor NSAID
|
|
MICROBIOLOGY
|
After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, an NSAID. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.
|
|
CONTRAINDICATIONS & WARNINGS
|
Increased Bleeding Time, Delayed Healing, Corneal Effects (Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation.
|
|
Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDs).
|
|
PEDIATRIC USE
|
The safety and effectiveness of NEVANAC 0.1% in pediatric patients below the age of 10 years have not been established.
|
|
PREGNANCY
|
Teratogenic Effect Pregnancy Category C: Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, NEVANAC 0.1% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Prostaglandin biosynthesis inhibitors harm the fetal cardiovascular system.
|
